Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1-2 Dose-escalation and Expansion Study of ST316 in Subjects With Selected Advanced Unresectable and Metastatic Solid Tumors

NCT05848739 is registered in ClinicalTrials.gov with Sapience Therapeutics as lead sponsor.

NCT NCT05848739
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05848739 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1-2 Dose-escalation and Expansion Study of ST316 in Subjects With Selected Advanced Unresectable and Metastatic Solid Tumors
Lead sponsor
Sapience Therapeutics
Phase
Phase 1
Overall status
Active, not recruiting
Start date
June 5, 2023
Completion date
December 31, 2027
Enrollment
130 (estimated)
Sites
11

Conditions

As the registry lists them; a condition with its own page is linked.

colon cancer, metastatic colon cancer